Why are T cells tolerant to hepatitis B virus?

Oct 14, 2008

The level of PD-1 expression has been proved by recent studies to be positively correlated with the extent of HBV-specific T cell impairments. However, the degree of T cell exhaustion which affects the disease statuses of hepatitis B patients has so far been only evaluated in restricted and small groups of patients between those with established chronicity and subjects with acute HBV infection. Besides, whether levels of PD-1 expression on T cells differ between acute exacerbation of hepatitis B and chronic HBV infected patients is still unknown.

A research article to be published on July 28, 2008 in the World Journal of Gastroenterology addresses this question. The research team led by Shu-Ling Zhang from Tongji Medical College of Huazhong University of Science and Technology in China examined the expression of PD-1 on antigen specific CD8+ T cells in peripheral blood of chronic hepatitis B (CHB) and acute exacerbation of hepatitis B (AEHB) patients.

They found that the levels of PD-1 on total CD8+ T cells in CHB patients were significantly higher than those in AEHB patients and healthy individuals. Conversely, lower frequencies of HBV-specific CD8+ T cells were detected in samples from chronic patients compared to AEHB patients. Our results confirmed reports that HBV specific CD8+ T-cell responses in peripheral blood were intensified in samples from AEHB patients than in those from patients with chronic hepatitis who remains viral persistence.

Besides, there was a significant positive correlation between HBV viral load and percentage of PD-1 expression on CD8+ T cells in CHB and AEHB group of subjects. However, PD-1 expression was not in association with disease flare-ups indicator alanine aminotransferase (ALT). This study clarified the correlation between PD-1 expression and two different HBV infection statuses.

Source: World Journal of Gastroenterology

Explore further: A real-time tracking system developed to monitor dangerous bacteria inside the body

add to favorites email to friend print save as pdf

Related Stories

Bristol-Myers pitches its cancer medicine pipeline

Jun 06, 2011

(AP) -- Bristol-Myers Squibb Co. executives said Monday they have more than a half-dozen drugs in testing against different cancers and could get important data on them and possibly a couple of approvals this year.

Recommended for you

Team finds key signaling pathway in cause of preeclampsia

6 hours ago

A team of researchers led by a Wayne State University School of Medicine associate professor of obstetrics and gynecology has published findings that provide novel insight into the cause of preeclampsia, the leading cause ...

Rapid test to diagnose severe sepsis

10 hours ago

A new test, developed by University of British Columbia researchers, could help physicians predict within an hour if a patient will develop severe sepsis so they can begin treatment immediately.

User comments : 0